Powered by a $70m cash infusion, Dicerna Pharmaceuticals Inc. is ready to move forward with a new focus on liver diseases. The RNA interference (RNAi) drug developer, like others working in the field, has seen its share of disappointments over the last decade, but is plowing ahead with a next-generation technology platform and a new focus on rare diseases and chronic liver disease.
"I think this generation of this technology is going to be the breakthrough generation for the industry," CEO Douglas Fambrough...







